Axsome Therapeutics Revenue and Competitors

Location

$207M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Axsome Therapeutics's estimated annual revenue is currently $4.8M per year.(i)
  • Axsome Therapeutics received $24.0M in venture funding in March 2019.
  • Axsome Therapeutics's estimated revenue per employee is $9,205
  • Axsome Therapeutics's total funding is $207M.

Employee Data

  • Axsome Therapeutics has 522 Employees.(i)
  • Axsome Therapeutics grew their employee count by 41% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.1M3-25%N/AN/A
#2
$5.9M356%N/AN/A
#3
$34.7M182-1%N/AN/A
#4
$5.2M670%$10MN/A
#5
$2M130%N/AN/A
#6
$7.5M370%$51.6MN/A
#7
$0.9M2-33%N/AN/A
#8
$4.3M21-16%$3.3MN/A
#9
$4.2M190%N/AN/A
#10
$4.3M56-8%$118MN/A
Add Company

Axsome Therapeutics is a biopharmaceutical company developing novel therapies for the treatment of CNS disorders. Axsome has a balanced portfolio of clinical development stage as well as research stage product candidates. The company is based in New York City.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$207M

Total Funding

522

Number of Employees

$4.8M

Revenue (est)

41%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Axsome Therapeutics's People

NameTitleEmail/Phone
1
Director, CMCReveal Email/Phone
2
Specialty Account ManagerReveal Email/Phone
3
Specialty Account ManagerReveal Email/Phone
4
Specialty Account ManagerReveal Email/Phone
5
Regional Business DirectorReveal Email/Phone
6
Contract Senior CRA IIReveal Email/Phone
7
Director Clinical OperationsReveal Email/Phone
8
Specialty Account ManagerReveal Email/Phone
9
Regional Business DirectorReveal Email/Phone
10
Specialty Account ManagerReveal Email/Phone

Axsome Therapeutics News

2022-04-17 - Axsome Therapeutics Shares Rally After Positive AXS-05 Update AXSM

Shares of Axsome Therapeutics Inc. rose more than 20% on Tuesday after the biopharmaceutical company reported positive developments in its...

2022-04-17 - Axsome Therapeutics (AXSM) Stock: Why The Price Surged Over 25% Today

The stock price of Axsome Therapeutics Inc (NASDAQ: AXSM) increased by over 25% pre-market today. Investors are responding positively to...

2022-04-17 - Why Axsome Therapeutics Is Jumping Higher on Tuesday

AXS-05 could be the first drug developed by Axsome Therapeutics to reach commercialization, but it probably won't become the company's first...

2019-09-08 - The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$84.8M522-16%N/A
#2
$249.2M522-25%N/A
#3
$87.4M523-10%$295.1M
#4
$146.6M52446%N/A
#5
$220.4M524-3%N/A

Axsome Therapeutics Funding

DateAmountRoundLead InvestorsReference
2016-11-11$20.0MUndisclosedSilicon Valley BankArticle
2017-12-04$9.5MUndisclosedH.C. Wainwright & CoArticle
2019-03-07$24.0MUndisclosedSilicon Valley BankArticle